| Literature DB >> 35649590 |
Oriol Cunillera Puértolas1,2, Sara Contreras-Martos1,2, Mercè Marzo-Castillejo1,2, Darío López Gallegos3, Mateo Acedo Anta4,5, Jesús Almeda Ortega1,2, Joan Colom6, Josep Basora7, Betlem Salvador-Gonzalez8.
Abstract
OBJECTIVES: To assess the impact of relaxing the state of alarm restrictions on SARS-CoV-2 infections at 14 days among people attending reopened nightclub venues.Entities:
Keywords: COVID-19; health policy; public health
Mesh:
Year: 2022 PMID: 35649590 PMCID: PMC9160590 DOI: 10.1136/bmjopen-2021-058595
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 3.006
Inclusion and exclusion criteria for study participants (volunteers and staff groups) attending the nightlife mass gathering event
| Inclusion criteria | Exclusion criteria |
| 1. Aged over 17 years | 1. Declaring to have had a positive RT-PCR or Ag-RDT in the last 7 days |
| 2. Living in Sitges area and Barcelona | 2. Presenting symptoms associated with COVID-19 in the last 7 days (according to Catalan Health Department protocols at least one of these: fever, persistent cough, shortness of breath, anosmia, ageusia at least two of the following: sore throat, a cold, fatigue, myalgia, headache, vomiting or diarrhoea stomachache |
| 3. Having a personal card from the Catalan public healthcare system | |
| 4. A negative Ag-RDT the same afternoon (provided by the organisation) | |
| 3. Having had close contact with someone infected in the last 10 days | |
| 4. Having had close contact with someone suspected to have COVID-19 in the last 48 hours |
Ag-RDT, rapid antigen diagnostic test; RT-PCR, reverse-transcription PCR.
Figure 1Participant flow chart. Ag-RDT, rapid antigen diagnostic test; EHR, electronic health record.
Sample characteristics and outcomes, overall and by subgroup
| n | Missing | Global | Organisers (n=18) | Security personnel (n=9) | Club workers (n=32) | Study participants (n=332) | P value | |
| Age: median (IQR) | 391 | 0 | 37.00 (23.00–50.00) | 54.00 (48.25–57.00) | 41.00 (38.00–46.00) | 29.00 (25.00–40.25) | 35.50 (23.00–50.00) | <0.001 |
| Age: mean (SD) | 37.54 (15.53) | 51.67 (8.60) | 41.44 (6.95) | 33.06 (10.53) | 37.10 (15.99) | <0.001 | ||
| Gender: n (%) | 391 | 0 | 0.017 | |||||
| Women | 173 (44.25) | 8 (44.44) | 0 (0.00) | 10 (31.25) | 155 (46.69) | |||
| Men | 218 (55.75) | 10 (55.56) | 9 (100.00) | 22 (68.75) | 177 (53.31) | |||
| MEDEA deprivation index: median (IQR) | 374 | 17 | −0.32 (−0.32 to 0.48) | −0.32 (–0.32 to –0.14) | 0.64 (0.48–1.07) | −0.32 (–0.32 to 0.64) | −0.32 (–0.32 to 0.48) | 0.022 |
| MEDEA deprivation index: mean (SD) | 0.04 (0.59) | −0.03 (0.64) | 0.79 (0.49) | 0.09 (0.67) | 0.02 (0.58) | 0.015 | ||
| MEDEA deprivation index categories: n (%) | 391 | 0 | <0.001 | |||||
| Least deprived septiles (28.6%) | 16 (4.09) | 0 (0.00) | 0 (0.00) | 1 (3.12) | 15 (4.52) | |||
| Most deprived septiles (28.6%) | 98 (25.06) | 3 (16.67) | 5 (55.56) | 9 (28.12) | 81 (24.40) | |||
| 3 central septiles (42.8%) | 260 (66.50) | 13 (72.22) | 1 (11.11) | 21 (65.62) | 225 (67.77) | |||
| No MEDEA | 17 (4.35) | 2 (11.11) | 3 (33.33) | 1 (3.12) | 11 (3.31) | |||
| Previous infection: n (%) | 391 | 0 | 35 (8.95) | 3 (16.67) | 0 (0.00) | 2 (6.25) | 30 (9.04) | 0.477 |
| Previous infection date: median (IQR) | 35 | 356 | 2 Nov 2020 (17 Aug 2020–8 Jan 2021) | 13 Jan 2021 (4 Nov 2020–17 Jan 2021) | – | 19 Jan 2021 (2 Jan 2021–5 Feb 2021) | 15 Oct 2020 (12 Aug 2020–3 Jan 2021) | 0.256 |
| First vaccination: n (%) | 391 | 0 | 42 (10.74) | 1 (5.56) | 0 (0.00) | 2 (6.25) | 39 (11.75) | 0.456 |
| Vaccine 1 company: n (%) | 42 | 349 | ||||||
| BioNTech/Pfizer | 17 (40.48) | 1 (100.00) | – | 0 (0.00) | 16 (41.03) | |||
| Moderna | 8 (19.05) | 0 (0.00) | – | 2 (100.00) | 6 (15.38) | |||
| Oxford/AstraZeneca | 17 (40.48) | 0 (0.00) | – | 0 (0.00) | 17 (43.59) | |||
| Second vaccination: n (%) | 391 | 0 | 23 (5.88) | 1 (5.56) | 0 (0.00) | 2 (6.25) | 20 (6.02) | 0.900 |
| Vaccine 2 company: n (%) | 23 | 368 | ||||||
| BioNTech/Pfizer | 15 (65.22) | 1 (100.00) | – | 0 (0.00) | 14 (70.00) | |||
| Moderna | 7 (30.43) | 0 (0.00) | – | 2 (100.00) | 5 (25.00) | |||
| Oxford/AstraZeneca | 1 (4.35) | 0 (0.00) | – | 0 (0.00) | 1 (5.00) | |||
| Vaccinated and infected: n (%) | 391 | 0 | 73 (18.67) | 4 (22.22) | 0 (0.00) | 3 (9.38) | 66 (19.88) | 0.225 |
| Follow-up Ag-RDT at 6 days: n (%) | 391 | 0 | 0.069 | |||||
| Negative result | 344 (87.98) | 17 (94.44) | 6 (66.67) | 31 (96.88) | 290 (87.35) | |||
| Not attending | 47 (12.02) | 1 (5.56) | 3 (33.33) | 1 (3.12) | 42 (12.65) | |||
| Extra tests at 14 days: n (%) | 18 | 373 | – | |||||
| RT-PCR | 13 (72.22) | – | 2 (100.00) | 2 (100.00) | 9 (64.29) | |||
| Ag-RDT | 5 (27.78) | – | 0 (0.00) | 0 (0.00) | 5 (35.71) | |||
| Test results at 14 days: n (%) | 18 | 373 | – | |||||
| Negative result | 18 (100.00) | – | 2 (100.00) | 2 (100.00) | 14 (100.00) |
Ag-RDT, rapid antigen diagnostic test; RT-PCR, Real-time Reverse-Transcription Polymerase Chain Reaction.